Sana Biotechnology (NASDAQ: SANA) is one of 197 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Sana Biotechnology to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.
This is a breakdown of current ratings for Sana Biotechnology and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sana Biotechnology Competitors||1115||4439||9773||185||2.58|
Insider & Institutional Ownership
47.3% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 52.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.8% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Sana Biotechnology and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sana Biotechnology Competitors||-22,838.38%||-121.87%||-32.56%|
Earnings and Valuation
This table compares Sana Biotechnology and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sana Biotechnology||N/A||-$285.30 million||-2.17|
|Sana Biotechnology Competitors||$606.09 million||$28.84 million||24.48|
Sana Biotechnology’s peers have higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Sana Biotechnology peers beat Sana Biotechnology on 8 of the 12 factors compared.
About Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.